A Phase 1b Dose-Escalation Study to Evaluate the Safety and Tolerability of the Addition of the Aminopeptidase Inhibitor CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours.
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2012
At a glance
- Drugs Paclitaxel; Tosedostat
- Indications Solid tumours
- Focus Adverse reactions
- 13 Sep 2007 New trial record.